An experimental Pfizer sickle cell treatment failed to meet the main goal in a late-stage trial for patients aged 16 and ...

Theresa Gaffney is the lead Morning Rounds writer and reports on health care, new research, and public policy, with a ...

In a highly unusual move, a small biotech has disclosed a rejection letter from the FDA in hopes of rallying support for ...

Kennedy would be less hazardous if he decided to do cardiac surgery. Then he would kill people only one at a time,” writes ...

High publishing costs and a crumbling peer review infrastructure are symptoms of deeper structural issues in research.

The top executives running the health care industry’s blue-chip companies amassed generational wealth in 2024, even as many ...

Morning. Today, we examine the plush pay packages of health care’s top CEOs in 2024. Also, we discuss Stealth BioTherapeutics’ efforts to rally support behind its Barth syndrome drug, and hear more ...

Last November, in the days following Donald Trump’s election, leaders at the National Institutes of Health began discussing ...

A draft of RFK Jr.'s much-awaited strategy for a healthier America softens rhetoric on agricultural chemicals and stresses ...

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

A new study suggests that, after having a specialized AI tool taken away, clinicians were less proficient at colonoscopies.

With U.S. funding for science at risk, a longtime advocate sees ‘light at the end of the tunnel’ in Washington.